Abramson Cancer Center

Clinical Trials

Multiple Myeloma Trials

• A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute GVHD (BMT CTN 0802)


• A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed / Refractory Myeloma


• A Pilot Phase I/II, Dual-Cohort, Two-Site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous Tcells Expressing a High Affinity TCR Specific for MAGE-A3/6 or NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma


• A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapaymycin Hydroxychloroquine in Patients with Relapsed or Refractory Myeloma


• An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy


• Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma


• High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes)


• Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)


• Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol® (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance


• Randomised Phase II Study Evaluating the Anti-tumour Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy


• Rhodiola Rosea Therapy of Major Depressive Disorder


• Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation


• Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A